Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlormadinone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 7/20 | 1.00 |
| ▸ | AR | P10275 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlormadinone Acetate SCHEMBL29430402 | 1.00 | AR (1.00) | ARCYP3A4NR3C1PGRSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL11795531 | 1.00 | AR (1.00) | ARCYP3A4NR3C1PGRSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL40360 | 1.00 | AR (1.00) | ARCYP3A4NR3C1PGRSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL15046 | 1.00 | AR (1.00) | ARCYP3A4NR3C1PGRSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL1460594 | 1.00 | AR (1.00) | ARCYP3A4NR3C1PGRSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL1460593 | 1.00 | AR (1.00) | ARCYP3A4NR3C1PGRSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL23908022 | 0.99 | AR (0.98) | ARCYP3A4NR3C1PGRSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL1250000 | 0.90 | AR (0.82) | ARCYP3A4NR3C1PGRSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL9572032 | 0.90 | CYP3A4 (0.80) | ARCYP3A4NR3C1PGRSMN1; SMN2 | |
| SCHEMBL11512932 | 0.89 | AR (0.81) | ARCYP3A4NR3C1PGRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20080255253-A1 | ANIMAL MODEL FOR PROSTATIC STROMAL HYPERPLASIA | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7417175-B2 | Interstitial prostatism model animal | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20040139486-A1 | Interstitial prostatism model animal | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1393623-A1 | INTERSTITIAL PROSTATISM MODEL ANIMAL | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | PGR 4821/4885AR 4752/4885CYP3A4 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.